Salute e Benessere
BioVaxys Announces Debt Settlement Agreement, Extension of Private Placement Closing Date and Closing of The Fourth and Final Tranche of Private Placement
All securities proposed to be issued in connection with the Debt Settlement will be subject to a statutory hold period of at least four months from the date of issuance in accordance with applicable securities legislation. The closing of the Debt Settlement is conditional upon the receipt of all applicable corporate and regulatory approvals, including the acceptance of the Canadian Securities Exchange.
In addition, the Company announces, further to its news releases of January 10, 2025 , January 23, 2025 , and February 7, 2025 , an extension of its previously announced non-brokered private placement offering of units of the Company (" ") at a price of $0.05 per Unit (the " ") and the closing of the fourth and final tranche (the " ") of its Private Placement with the issuance of 2,000,000 Units at a price of $0.05 per Unit for aggregate gross proceeds of $100,000 .
Each Unit consists of one (1) common share in the capital of the Company (each, a " ") and one (1) whole Share purchase warrant (each, a " "), whereby each Warrant is convertible into one additional Share at an exercise price of $0.15 until February 18, 2027 , being the date that is 24 months from the date of issue.
The Company intends to use the net proceeds of the Fourth Tranche for working capital. No finder's fees were paid in connection with the Fourth Tranche. All securities issued pursuant to the Fourth Tranche are subject to a statutory hold period expiring June 19, 2025 , being the date that is four months and one day from the date of issuance in accordance with applicable securities legislation.
This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States . The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " "), or any state securities laws, and may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada , is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.
The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens.
BioVaxys common shares are listed on the Canadian Securities Exchange under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the U.S. on the OTC Markets (OTCQB marketplace). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
Signed " "
James Passin , Chief Executive Officer
Phone: +1 740 358 0555
Logo: https://mma.prnewswire.com/media/2415135/5174106/BioVaxys_Technology_Corp_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-announces-debt-settlement-agreement-extension-of-private-placement-closing-date-and-closing-of-the-fourth-and-final-tranche-of-private-placement-302379591.html